EndoPredict® Prognostic Test for Breast Cancer

EndoPredict is a second-generation gene expression test for the detection of ER-positive (estrogen receptor-positive) and HER2-negative (human epidermal growth factor receptor 2-negative) (ER+/HER2-) early-stage recurrent breast cancer, which offers enhanced accuracy by combining molecular data with clinical and pathological factors.

• Validated for both premenopausal and postmenopausal women;
• provides an accurate, individualized assessment of the risk of distant recurrence of breast cancer over a 10-year period;
• Suitable for testing RNA samples from formalin-fixed, paraffin-embedded (FFPE) tumor tissue obtained from both biopsies and surgical specimens;
• Compatible with the QuantStudio™ 5 Dx real-time PCR system (Thermo Fisher Scientific) and the corresponding EndoPredict template files;
• The test is approved for diagnostic use and holds a Certificate of Conformity for in vitro diagnostic (IVD) medical devices in the European Economic Area (CE-IVD).